Anti-Coagulants - Serbia

Serbia

In Serbia, the Anti-Coagulants market is expected to see a projected revenue of US$12.86m in 2024.
Looking ahead, it is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of 7.78%, resulting in a market volume of US$18.70m by 2029.
When compared on a global scale, United States is forecasted to generate the highest revenue in this market, with an estimated US$16,740.00m in 2024.
Serbia's anti-coagulant market is witnessing a surge in demand for direct oral anticoagulants due to their ease of use and potential for improved patient outcomes.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Coagulants market in Serbia has been gaining traction in recent years.

Customer preferences: Serbia has a rapidly aging population, which has led to an increase in the incidence of cardiovascular diseases. As a result, there has been a growing demand for anticoagulant drugs in the country. Patients in Serbia prefer oral anticoagulants over injectable ones due to their convenience.

Trends in the market: The Anti-Coagulants market in Serbia has been witnessing a shift towards the use of newer oral anticoagulants such as Factor Xa inhibitors and direct thrombin inhibitors. The shift is due to the advantages of these drugs, such as the lower risk of bleeding and the lack of need for regular monitoring. These drugs have been gaining popularity among patients and healthcare professionals in Serbia.

Local special circumstances: Serbia has a complex healthcare system, which has resulted in limited access to healthcare services in some parts of the country. This has led to a lack of awareness among patients and healthcare professionals about the benefits of newer oral anticoagulants. As a result, there is a need for increased education and awareness campaigns to improve the uptake of these drugs in the country.

Underlying macroeconomic factors: The Serbian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. The government has been investing in improving the healthcare infrastructure and increasing access to healthcare services in the country. This has led to an increase in the availability of anticoagulant drugs in Serbia. Additionally, the country has been making efforts to align its healthcare system with EU standards, which has led to an increase in the availability of newer oral anticoagulants in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.